Anti-CTLA4 therapeutic antibody (Pre-made Quavonlimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Order information

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-460-1mg	1mg	3090
GMP-Bios-ab-460-10mg	10mg	21890
GMP-Bios-ab-460-100mg	100mg	148000
GMP-Bios-ab-460-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Anti-CTLA4 therapeutic antibody (Pre-made Quavonlimab biosimilar,Whole mAb)
INN Name	Quavonlimab
Target	CTLA4
Format	Whole mAb
Derivation
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2019
Year Recommended	2020
Companies	Merck
Conditions Approved	na
Conditions Active	Non-small cell lung cancer;Malignant melanoma;Renal cell carcinoma;Solid tumours
Conditions Discontinued	na
Development Tech	na